Tarsus officer to sell $800K in stock in 2026

Rhea-AI Filing Summary

Tarsus Pharmaceuticals, Inc. (TARS) received a notice that officer Bobak Azamian, through the Bobak Azamian Living Trust, intends to sell 10,000 shares of common stock under Rule 144, with an indicated aggregate market value of $800,568.71, through Merrill Lynch on NASDAQ.

The shares to be sold were originally acquired on January 13, 2017 in a private placement. In the preceding three months, the Bobak Azamian Living Trust sold an additional 10,000 shares of Tarsus common stock on June 17, 2026 for proceeds of $615,473.27.

Key Figures

Shares to be sold under Rule 144: 10,000 shares Aggregate market value of proposed sale: $800,568.71 Shares sold in past 3 months: 10,000 shares +3 more

6 metrics

Shares to be sold under Rule 144 10,000 shares Common stock of Tarsus Pharmaceuticals, Inc. to be sold by the Bobak Azamian Living Trust

Aggregate market value of proposed sale $800,568.71 Value of 10,000 TARS shares indicated in the Rule 144 notice

Shares sold in past 3 months 10,000 shares Common stock sold by the Bobak Azamian Living Trust on June 17, 2026

Proceeds from past 3‑month sale $615,473.27 Total proceeds from 10,000 TARS shares sold on June 17, 2026

Acquisition date of shares to be sold January 13, 2017 Original acquisition date in a private placement

Planned sale date reference September 2, 2026 Date associated with the securities information and notice

Key Terms

Rule 144, private placement, aggregate market value, Form 144, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

private placement financial

"COMMON | 01/13/2017 | PRIVATE PLACEMENT | TARSUS PHARMACEUTICALS INC"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

aggregate market value financial

"| 10000 | 800568.71 | 43882996 | 09/02/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Living Trust financial

"BOBAK AZAMIAN LIVING TRUST 17700 LAGUNA CANYON ROAD FL 4 IRVINE CA 92618"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for TARS?

The filing states that 10,000 shares of Tarsus Pharmaceuticals, Inc. (TARS) common stock held in the Bobak Azamian Living Trust are intended to be sold under Rule 144, with an indicated $800,568.71 aggregate market value through Merrill Lynch on NASDAQ.

Who is selling TARS shares according to this Form 144?

The notice identifies Bobak Azamian, an officer of Tarsus Pharmaceuticals, Inc., with the transaction taking place in the Bobak Azamian Living Trust, where Bobak Azamian is trustee. The trust is the account from which the TARS shares are to be sold.

How many TARS shares are proposed to be sold and at what value?

The Form 144 indicates a proposed sale of 10,000 shares of TARS common stock, with an aggregate market value of approximately $800,568.71. The shares are to be sold through Merrill Lynch on NASDAQ.

When were the TARS shares to be sold under this Form 144 originally acquired?

The 10,000 TARS shares covered by this notice were acquired on January 13, 2017 in a private placement by Tarsus Pharmaceuticals, Inc., according to the acquisition information provided in the filing.

What prior TARS share sales by this person occurred in the last three months?

During the past three months, the Bobak Azamian Living Trust sold 10,000 shares of TARS common stock on June 17, 2026 for total proceeds of $615,473.27, as reported in the Form 144 section on recent sales.

Which broker is handling the planned TARS share sale in this Form 144?

The planned sale of 10,000 TARS shares is listed as being executed through Merrill Lynch, with an office at 520 Newport Center Drive, 20th Floor, Newport Beach, CA 92660, and the shares are to be sold on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 02:41 PM EDT Accepted by SEC EDGAR 09/02/2026 - 02:39 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001827672
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TARSUS PHARMACEUTICALS INC
SEC File Number	001-39614
Address of Issuer	17700 LAGUNA CANYON ROAD FL 4 IRVINE CALIFORNIA 92618
Phone	949-418-1801
Name of Person for Whose Account the Securities are To Be Sold	BOBAK AZAMIAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	MERRILL LYNCH 520 NEWPORT CENTER DRIVE 20TH FLOOR NEWPORT BEACH CA 92660	10000	800568.71	43882996	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	01/13/2017	PRIVATE PLACEMENT	TARSUS PHARMACEUTICALS INC			10000	01/13/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
BOBAK AZAMIAN LIVING TRUST 17700 LAGUNA CANYON ROAD FL 4 IRVINE CA 92618	COMMON	06/17/2026	10000	615473.27

144: Remarks and Signature

Remarks	THIS TRANSACTIONTOOK PLACE IN THE BOBAK AZAMIAN LIVING TRUST, BOBAK AZAMIAN TRUSTEE
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	BOBAK AZAMIAN
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)